Niacinamide 500 mg by Bluebonnet — Ingredients, Evidence & Safety

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Vitamin B3: 500mg is 14.3× the Tolerable Upper Intake Level (35mg)

The safety score is low because the 500mg dose of Niacinamide is more than 14 times the recommended maximum daily limit of 35mg.

Label Data

1 Capsule(s) Serving Size

Vitamin Product Type

100% Evidence Coverage

Supplement Facts — Evidence Check

Vitamin B3

500 mg (3125% DV)

⚠️ Exceeds Tolerable Upper Intake Level by 14.3× (UL: 35 mg) 📚 193 studies (Tier A: 5, B: 63)

RDA 14mg This product: 500mg UL 35mg

Other Ingredients

Kosher Vegetable Capsules Vegetable Cellulose Vegetable Magnesium Stearate

Label Claims — Verification

❓ Nutrient

❓ All Other

All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Vegan Vegetarian Adult (18 - 50 Years) Kosher Gluten Free Dairy Free Sugar Free

Product Information

📋 Directions for Use

Directions: As a dietary supplement, take one capsule daily, preferably with a meal or as directed by a healthcare practitioner.

🧪 Formulation Notes

Bluebonnet’s Niacinamide 500 mg Capsules contain niacinamide in its purest crystalline form.

Bluebonnet’s KOF-K Certification #K-0000700

Made with non GMO ingredients

Vegan

Free of milk, egg, fish, crustacean shellfish, tree nuts, peanuts, wheat and soybeans. Also free of corn, yeast, gluten, barley, rice, sodium and sugar.

Additional Information

Available in easy-to-swallow vegetable capsules for maximum assimilation and absorption.

Made with non GMO ingredients

Vegan

K parve

Gluten free

Product Details

UPC / SKU 7 43715 00466 5

DSLD Entry Date 2019-07-24

Product Type Vitamin

Form Capsule

Brand Bluebonnet

DSLD ID 204047

Data Updated 2026-04-11

Research Evidence

241 Research Sources

55 Avg Quality Score

113 Meta Analysis

75 Systematic Review

32 Rct

11 Clinical Trial

3 Other

3 Regulatory Source

1 Cochrane Review

1 Narrative Review

1 Openfda Safety

A Niacin for primary and secondary prevention of cardiovascular events

Meta Analysis The Cochrane database of systematic reviews 2017

PubMed DOI Cochrane

A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases

Meta Analysis BMJ (Clinical research ed.) 2013

PubMed DOI

A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients

Meta Analysis BMJ (Clinical research ed.) 2014

PubMed DOI

A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk

Meta Analysis Nature medicine 2024

PubMed DOI

A Meta-analysis and imputation refines the association of 15q25 with smoking quantity

Meta Analysis Nature genetics 2010

PubMed DOI

A Genome-wide meta-analyses identify multiple loci associated with smoking behavior

Meta Analysis Nature genetics 2010

PubMed DOI

A Antidepressants for smoking cessation

Meta Analysis The Cochrane database of systematic reviews 2014

PubMed DOI

A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne

Meta Analysis The Cochrane database of systematic reviews 2020

PubMed DOI Cochrane

B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis

Meta Analysis JAMA network open 2019

PubMed DOI

B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis

Meta Analysis JAMA 2016

PubMed DOI

View all evidence for Niacin →